Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 29, 2020 Filed Jan 31, 2020 21:48 UTC |
Hadfield RobertGeneral Counsel and Secretary
|
GrantCommon Stock | 59,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005783 · doc4.xml · nonDerivative · entry 1 Hadfield Robert · CIK 0001630687 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,819 F1 · shares: 19,700 shares shall vest on each of 12/31/2020, 12/31/2021 and 12/31/2022. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:47 UTC |
De Groot EleanorEVP, GM Cell Therapy
|
GrantEmployee Stock Option (right to buy) · Derivative | 82,600 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001209191-20-005781 · doc4.xml · derivative · entry 2 De Groot Eleanor · CIK 0001780420 · EVP, GM Cell Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,600 Underlying: Common Stock · 82,600 shares Expires 2030-01-29 F2 · derivative.exercise_date: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2019. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:47 UTC |
De Groot EleanorEVP, GM Cell Therapy
|
GrantCommon Stock | 53,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005781 · doc4.xml · nonDerivative · entry 1 De Groot Eleanor · CIK 0001780420 · EVP, GM Cell Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,033 F1 · shares: 17,900 shares shall vest on each of 12/31/2020, 12/31/2021 and 12/31/2022. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:45 UTC |
Cooper Laurence James NeilDirector · Chief Executive Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 264,200 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001209191-20-005780 · doc4.xml · derivative · entry 2 Cooper Laurence James Neil · CIK 0001641506 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,200 Underlying: Common Stock · 264,200 shares Expires 2030-01-29 F2 · derivative.exercise_date: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2019. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:45 UTC |
Cooper Laurence James NeilDirector · Chief Executive Officer
|
GrantCommon Stock | 171,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005780 · doc4.xml · nonDerivative · entry 1 Cooper Laurence James Neil · CIK 0001641506 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,904,973 F1 · shares: 57,234 shares shall vest on 12/31/2020 and 57,233 shares shall vest on each of 12/31/2021 and 12/31/2022. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 22:09 UTC |
Lafond Kevin GSVP, Treasurer & CAO
|
SaleCommon Stock | 21,570 | $4.55 | $98,143.50 |
DisclosureSEC source: 0001209191-20-001176 · doc4.xml · nonDerivative · entry 1 Lafond Kevin G · CIK 0001429559 · SVP, Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,985 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.46 to $4.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 22:10 UTC |
MAUNEY DAVID M MDPresident
|
SaleCommon Stock | 22,394 | $4.55 | $101,892.70 |
DisclosureSEC source: 0001209191-20-001180 · doc4.xml · nonDerivative · entry 1 MAUNEY DAVID M MD · CIK 0001305832 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,278 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.46 to $4.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 22:07 UTC |
Hadfield RobertGeneral Counsel and Secretary
|
SaleCommon Stock | 16,853 | $4.55 | $76,681.15 |
DisclosureSEC source: 0001209191-20-001173 · doc4.xml · nonDerivative · entry 1 Hadfield Robert · CIK 0001630687 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,719 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.46 to $4.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 22:06 UTC |
De Groot EleanorEVP, GM Cell Therapy
|
SaleCommon Stock | 24,890 | $4.55 | $113,249.50 |
DisclosureSEC source: 0001209191-20-001170 · doc4.xml · nonDerivative · entry 1 De Groot Eleanor · CIK 0001780420 · EVP, GM Cell Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,333 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.46 to $4.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 22:04 UTC |
Buck JillEVP, GM Gene Therapy
|
SaleCommon Stock | 27,923 | $4.55 | $127,049.65 |
DisclosureSEC source: 0001209191-20-001167 · doc4.xml · nonDerivative · entry 1 Buck Jill · CIK 0001780426 · EVP, GM Gene Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,710 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.46 to $4.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 22:11 UTC |
Pagan Douglas W.Director
|
GrantStock Option (right to buy) · Derivative | 25,281 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001209191-20-001183 · doc4.xml · derivative · entry 3 Pagan Douglas W. · CIK 0001628880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,281 Underlying: Common Stock · 25,281 shares Expires 2029-12-31 F3 · derivative.exercise_date: 100% of the shares subject to the option vest on December 31, 2020, subject to Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 22:11 UTC |
Pagan Douglas W.Director
|
Tax withholdingCommon Stock | 20,054 | $4.72 | $94,654.88 |
DisclosureSEC source: 0001209191-20-001183 · doc4.xml · nonDerivative · entry 2 Pagan Douglas W. · CIK 0001628880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,943 F2 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of a restricted stock grant. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 22:11 UTC |
Pagan Douglas W.Director
|
GrantCommon Stock | 15,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-001183 · doc4.xml · nonDerivative · entry 1 Pagan Douglas W. · CIK 0001628880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,997 F1 · shares: 15,890 shares vest on 12/31/2020. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 22:11 UTC |
Tarriff ScottDirector
|
GrantStock Option (right to buy) · Derivative | 50,562 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001209191-20-001186 · doc4.xml · derivative · entry 1 Tarriff Scott · CIK 0001469124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,562 Underlying: Common Stock · 50,562 shares Expires 2029-12-31 F1 · derivative.exercise_date: 100% of the shares subject to the option vest on December 31, 2020, subject to Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 22:08 UTC |
Hagen HeidiDirector
|
GrantCommon Stock | 31,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-001175 · doc4.xml · nonDerivative · entry 1 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,119 F1 · shares: 31,780 shares vest on 12/31/2020. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 22:09 UTC |
Lafond Kevin GSVP, Treasurer & CAO
|
GrantEmployee Stock Option (right to buy) · Derivative | 48,000 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001209191-20-001176 · doc4.xml · derivative · entry 2 Lafond Kevin G · CIK 0001429559 · SVP, Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2029-12-31 F3 · derivative.exercise_date: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2019. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 22:06 UTC |
Ezickson ElanDirector
|
Tax withholdingCommon Stock | 40,107 | $4.72 | $189,305.04 |
DisclosureSEC source: 0001209191-20-001171 · doc4.xml · nonDerivative · entry 2 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,887 F2 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of a restricted stock grant. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 22:06 UTC |
Ezickson ElanDirector
|
GrantCommon Stock | 31,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-001171 · doc4.xml · nonDerivative · entry 1 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,994 F1 · shares: 31,780 shares vest on 12/31/2020. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 22:03 UTC |
Braunstein ScottDirector
|
GrantCommon Stock | 31,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-001165 · doc4.xml · nonDerivative · entry 1 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,780 F1 · shares: 31,780 shares vest on 12/31/2020. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 22:02 UTC |
Bowden ChristopherDirector
|
GrantStock Option (right to buy) · Derivative | 50,562 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001209191-20-001164 · doc4.xml · derivative · entry 1 Bowden Christopher · CIK 0001608601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,562 Underlying: Common Stock · 50,562 shares Expires 2029-12-31 F1 · derivative.exercise_date: 100% of the shares subject to the option vest on December 31, 2020, subject to Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| December 30, 2019 Filed Dec 31, 2019 21:37 UTC |
Cooper Laurence James NeilDirector · Chief Executive Officer
|
SaleCommon Stock | 110,694 | $4.88 | $540,186.72 |
DisclosureSEC source: 0001209191-19-062290 · doc4.xml · nonDerivative · entry 2 Cooper Laurence James Neil · CIK 0001641506 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,733,273 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.79 to $5.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 27, 2019 Filed Dec 31, 2019 21:37 UTC |
Cooper Laurence James NeilDirector · Chief Executive Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 44,642 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001209191-19-062290 · doc4.xml · derivative · entry 3 Cooper Laurence James Neil · CIK 0001641506 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 487,171 Underlying: Common Stock · 44,642 shares Expires 2029-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2018. Read SEC document |
| December 27, 2019 Filed Dec 31, 2019 21:37 UTC |
Cooper Laurence James NeilDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 44,642 | $2.24 | $99,998.08 |
DisclosureSEC source: 0001209191-19-062290 · doc4.xml · nonDerivative · entry 1 Cooper Laurence James Neil · CIK 0001641506 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,843,967 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 22:07 UTC |
Lafond Kevin GSVP, Treasurer & CAO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 11,667 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001209191-19-058365 · doc4.xml · derivative · entry 3 Lafond Kevin G · CIK 0001429559 · SVP, Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,667 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 22:07 UTC |
Lafond Kevin GSVP, Treasurer & CAO
|
SaleCommon Stock | 11,667 | $5.25 | $61,251.75 |
DisclosureSEC source: 0001209191-19-058365 · doc4.xml · nonDerivative · entry 2 Lafond Kevin G · CIK 0001429559 · SVP, Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,555 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2019. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 22:07 UTC |
Lafond Kevin GSVP, Treasurer & CAO
|
Exercise / conversionCommon Stock | 11,667 | $2.85 | $33,250.95 |
DisclosureSEC source: 0001209191-19-058365 · doc4.xml · nonDerivative · entry 1 Lafond Kevin G · CIK 0001429559 · SVP, Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 25, 2019 Filed Oct 30, 2019 01:09 UTC |
Bowden ChristopherDirector
|
GrantStock Option (right to buy) · Derivative | 94,031 | $0.00 Strike: $4.26 | $0.00 |
DisclosureSEC source: 0001209191-19-054401 · doc4.xml · derivative · entry 1 Bowden Christopher · CIK 0001608601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,031 Underlying: Common Stock · 94,031 shares Expires 2029-10-25 F1 · derivative.exercise_date: 100% of the shares subject to the option vest on October 8, 2021, subject to Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| July 22, 2019 Filed Jul 24, 2019 12:57 UTC |
Shukla SathEVP, Chief Financial Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001209191-19-042993 · doc4.xml · derivative · entry 1 Shukla Sath · CIK 0001782817 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-07-22 F1 · derivative.exercise_date: 100,000 shares subject to the option shall vest on 7/22/2020; 25,000 shares subject to the option shall vest on a quarterly basis thereafter. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 20:36 UTC |
Hagen HeidiDirector
|
GrantStock Option (right to buy) · Derivative | 93,922 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0001209191-19-037401 · doc4.xml · derivative · entry 1 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,922 Underlying: Common Stock · 93,922 shares Expires 2029-06-12 F1 · derivative.exercise_date: 93,922 shares vest on 6/13/2021. Read SEC document |
| May 07, 2019 Filed May 8, 2019 20:37 UTC |
CANNON JAMES ANTHONYDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001209191-19-028239 · doc4.xml · derivative · entry 2 CANNON JAMES ANTHONY · CIK 0001338533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2019-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| May 07, 2019 Filed May 8, 2019 20:37 UTC |
CANNON JAMES ANTHONYDirector
|
Exercise / conversionCommon Stock | 15,000 | $0.70 | $10,500.00 |
DisclosureSEC source: 0001209191-19-028239 · doc4.xml · nonDerivative · entry 1 CANNON JAMES ANTHONY · CIK 0001338533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2019 Filed Jan 8, 2019 21:27 UTC |
Lafond Kevin GSVP, Treasurer & CAO
|
GrantEmployee Stock Option (right to buy) · Derivative | 58,536 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001209191-19-002787 · doc4.xml · derivative · entry 2 Lafond Kevin G · CIK 0001429559 · SVP, Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,536 Underlying: Common Stock · 58,536 shares Expires 2029-01-06 F2 · derivative.exercise_date: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2018. Read SEC document |
| January 06, 2019 Filed Jan 8, 2019 21:27 UTC |
Lafond Kevin GSVP, Treasurer & CAO
|
GrantCommon Stock | 37,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002787 · doc4.xml · nonDerivative · entry 1 Lafond Kevin G · CIK 0001429559 · SVP, Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,555 F1 · shares: 12,374 shares shall vest on each of 12/31/2019, 12/31/2020 and 12/31/2021. Read SEC document |
| January 06, 2019 Filed Jan 8, 2019 21:25 UTC |
Hadfield RobertGeneral Counsel and Secretary
|
GrantEmployee Stock Option (right to buy) · Derivative | 185,391 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001209191-19-002782 · doc4.xml · derivative · entry 2 Hadfield Robert · CIK 0001630687 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,391 Underlying: Common Stock · 185,391 shares Expires 2029-01-06 F2 · derivative.exercise_date: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2018. Read SEC document |
| January 06, 2019 Filed Jan 8, 2019 21:25 UTC |
Hadfield RobertGeneral Counsel and Secretary
|
GrantCommon Stock | 117,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002782 · doc4.xml · nonDerivative · entry 1 Hadfield Robert · CIK 0001630687 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,572 F1 · shares: 39,191 shares shall vest on each of 12/31/2019 and 12/31/2020, and 39,190 shares shall vest on 12/31/2021. Read SEC document |
| January 06, 2019 Filed Jan 8, 2019 21:24 UTC |
Cooper Laurence James NeilDirector · Chief Executive Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 531,813 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001209191-19-002778 · doc4.xml · derivative · entry 4 Cooper Laurence James Neil · CIK 0001641506 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 531,813 Underlying: Common Stock · 531,813 shares Expires 2029-01-06 F4 · derivative.exercise_date: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2018. Read SEC document |
| January 06, 2019 Filed Jan 8, 2019 21:24 UTC |
Cooper Laurence James NeilDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 165,178 | $2.24 | $369,998.72 |
DisclosureSEC source: 0001209191-19-002778 · doc4.xml · nonDerivative · entry 3 Cooper Laurence James Neil · CIK 0001641506 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,799,325 F3 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grant. Read SEC document |
| January 06, 2019 Filed Jan 8, 2019 21:24 UTC |
Cooper Laurence James NeilDirector · Chief Executive Officer
|
GrantCommon Stock | 446,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002778 · doc4.xml · nonDerivative · entry 2 Cooper Laurence James Neil · CIK 0001641506 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,964,503 F2 · shares: Pursuant to the Issuer's option plan, the Reporting Person elected to receive fully vested shares of Common Stock in lieu of a cash bonus. Read SEC document |
| January 06, 2019 Filed Jan 8, 2019 21:24 UTC |
Cooper Laurence James NeilDirector · Chief Executive Officer
|
GrantCommon Stock | 337,266 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002778 · doc4.xml · nonDerivative · entry 1 Cooper Laurence James Neil · CIK 0001641506 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,518,075 F1 · shares: 112,422 shares shall vest on each of 12/31/2019, 12/31/2020 and 12/31/2021. Read SEC document |
| January 06, 2019 Filed Jan 8, 2019 21:22 UTC |
MAUNEY DAVID M MDPresident
|
GrantEmployee Stock Option (right to buy) · Derivative | 250,733 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001209191-19-002774 · doc4.xml · derivative · entry 2 MAUNEY DAVID M MD · CIK 0001305832 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,733 Underlying: Common Stock · 250,733 shares Expires 2029-01-06 F2 · derivative.exercise_date: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2018. Read SEC document |
| January 06, 2019 Filed Jan 8, 2019 21:22 UTC |
MAUNEY DAVID M MDPresident
|
GrantCommon Stock | 159,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002774 · doc4.xml · nonDerivative · entry 1 MAUNEY DAVID M MD · CIK 0001305832 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,672 F1 · shares: 53,004 shares shall vest on 12/31/2019 and 53,033 shares shall vest on each of 12/31/2020 and 12/31/2021. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 02:18 UTC |
Tarriff ScottDirector
|
GrantStock Option (right to buy) · Derivative | 126,700 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001209191-19-000590 · doc4.xml · derivative · entry 1 Tarriff Scott · CIK 0001469124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,700 Underlying: Common Stock · 126,700 shares Expires 2028-12-31 F1 · derivative.exercise_date: 126,700 options vest on 12/31/2019. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 02:17 UTC |
Pagan Douglas W.Director
|
GrantStock Option (right to buy) · Derivative | 63,350 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001209191-19-000589 · doc4.xml · derivative · entry 2 Pagan Douglas W. · CIK 0001628880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,350 Underlying: Common Stock · 63,350 shares Expires 2028-12-31 F2 · derivative.exercise_date: 63,350 options vest on 12/31/2019. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 02:17 UTC |
Pagan Douglas W.Director
|
GrantCommon Stock | 40,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-000589 · doc4.xml · nonDerivative · entry 1 Pagan Douglas W. · CIK 0001628880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,107 F1 · shares: 40,107 shares vest on 12/31/2019. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 02:16 UTC |
Lafond Kevin GSVP, Treasurer & CAO
|
Tax withholdingCommon Stock | 9,334 | $1.87 | $17,454.58 |
DisclosureSEC source: 0001209191-19-000588 · doc4.xml · nonDerivative · entry 3 Lafond Kevin G · CIK 0001429559 · SVP, Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,433 F1 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 02:16 UTC |
Ezickson ElanDirector
|
GrantCommon Stock | 80,214 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-000587 · doc4.xml · nonDerivative · entry 1 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,214 F1 · shares: 80,214 shares vest on 12/31/2019. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 02:15 UTC |
Cooper Laurence James NeilDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 16,156 | $1.87 | $30,211.72 |
DisclosureSEC source: 0001209191-19-000586 · doc4.xml · nonDerivative · entry 3 Cooper Laurence James Neil · CIK 0001641506 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,180,809 F1 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 02:14 UTC |
CANNON JAMES ANTHONYDirector
|
GrantStock Option (right to buy) · Derivative | 126,700 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001209191-19-000585 · doc4.xml · derivative · entry 2 CANNON JAMES ANTHONY · CIK 0001338533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,700 Underlying: Common Stock · 126,700 shares Expires 2028-12-31 F2 · derivative.exercise_date: 126,700 options vest on 12/31/2019. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 02:14 UTC |
Braunstein ScottDirector
|
GrantStock Option (right to buy) · Derivative | 126,700 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001209191-19-000584 · doc4.xml · derivative · entry 1 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,700 Underlying: Common Stock · 126,700 shares Expires 2028-12-31 F1 · derivative.exercise_date: 126,700 options vest on 12/31/2019. Read SEC document |
| December 30, 2018 Filed Jan 3, 2019 02:16 UTC |
Lafond Kevin GSVP, Treasurer & CAO
|
Tax withholdingCommon Stock | 13,100 | $1.66 | $21,746.00 |
DisclosureSEC source: 0001209191-19-000588 · doc4.xml · nonDerivative · entry 2 Lafond Kevin G · CIK 0001429559 · SVP, Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,767 F1 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.